Prostate Cancer - Results from #700

REVIEW UroToday

Radiation dose to rectum in high-dose-rate brachytherapy with a single implant and two fractions for prostate cancer, and its prediction by prostate volume, "Beyond the Abstract," by Morio Sato, MD January 7, 2015

The value of tumor volume in surgical specimen as a risk factor of biochemical recurrence of prostate cancer, "Beyond the Abstract," by Ricardo de la Roca, MD, PhD, et al December 17, 2014

Prostate health index vs %free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy, "Beyond the Abstract," by Daniela Terracciano, PhD, et al December 16, 2014

The potential for vulnerabilities to prostate cancer treatment disparities in HIV-infected men, "Beyond the Abstract," by Adam B. Murphy, et al December 13, 2014

The role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men, "Beyond the Abstract," by Suzanne M. Miller, PhD and John Scarpato, MA December 12, 2014

The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy, "Beyond the Abstract," by Michele Lanciotti, et al December 11, 2014

Regucalcin is an androgen-target gene in the rat prostate modulating cell-cycle and apoptotic pathways, "Beyond the Abstract," by Sílvia Socorro, PhD December 10, 2014

Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model, "Beyond the Abstract," by Juan Chen, et al December 10, 2014

Diagnostic performance and safety of a 3D, 14-core, systematic prostate biopsy method, "Beyond the Abstract," by Hideki Takeshita, MD, PhD and Satoru Kawakami, MD, PhD December 4, 2014

Minor variations in biopsy-assigned Gleason scores offer robust stratification of survival outcomes for men treated with external beam radiation therapy for prostate cancer, "Beyond the Abstract," by Chad G. Rusthoven, et al December 1, 2014

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer, "Beyond the Abstract," by Adam R. Metwalli, MD, Inger Lerra Rosner, MD, and Jennifer Cullen Meyer, PhD, MPH November 21, 2014

Management of metastatic prostate cancer therapy by integrating circulating tumor cell data with imaging and serum prostate-specific antigen measurement, "Beyond the Abstract," by Oscar Goodman, MD, PhD and Eric R. Schuur, PhD November 21, 2014

Dose perturbation due to catheter materials in high-dose-rate interstitial 192Ir brachytherapy, "Beyond the Abstract," by Luc Beaulieu, PhD, et al. November 19, 2014

The current state of focal therapy for the treatment of prostate cancer, "Beyond the Abstract," by Fernando Xavier Jácome-Pita November 18, 2014

Bisphenol A exposure and prostate cancer outcomes, "Beyond the Abstract," by Shuk-mei Ho and Pheruza Tarapore November 14, 2014

The ten most prevalent problems in prostate biopsy interpretation, "Beyond the Abstract," by Kenneth A. Iczkowski, MD November 7, 2014

CAPRIS (Cancer of the Prostate Identification Screening) - a research project by the Interest Group for Quality Assurance in the Work of Office-based Uro-oncologists (IQUO) in Germany, "Video Beyond the Abstract," Presented by Axel S. Merseburger November 7, 2014

Evidence of the safety and chemopreventive effect of green tea extract in preventing early as well as metastatic progression of prostate cancer, "Beyond the Abstract," by Jong Y. Park, PhD, MS, MPH November 6, 2014

Strategies for mitigating the complications of androgen deprivation therapy in men with prostate cancer, "Beyond the Abstract," by Carolyn A. Allan, et al November 6, 2014

Nanoways to overcome docetaxel resistance in prostate cancer, "Beyond the Abstract," by Meena Jaggi, PhD November 5, 2014

Page 36 of 57